Login to Your Account

Pharma: Other News To Note

Thursday, October 10, 2013
• Bayer Healthcare, of Whippany, N.J., said the FDA approved Adempas (riociguat) tablets to treat adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and to treat adults with pulmonary arterial hypertension to improve exercise capacity, improve WHO functional class and delay clinical worsening.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription